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Abstract
Diarrhea is a global health problem with high morbidity and mortality. In developing countries, acute 
diarrhea is most commonly caused by infectious pathogens. Regardless of the cause, diarrhea is primarily 
treated by fluid replacement therapy to decrease the risk of dehydration and death, although it does not affect 
the duration of diarrhea. Probiotics are able to shorten the duration of diarrhea in children, but its efficacy 
in adults is unclear. This study aimed to evaluate the benefit of probiotic in reducing the duration of acute 
diarrhea in adults as compared to placebo. Systematic search was done using four databases: PubMed, 
Scopus, ProQuest, and Embase, without limit on the year of publication. Randomized clinical trials were 
selected as the appropriate study design to answer the clinical question and two studies were considered 
relevant for appraisal. In conclusion, probiotics could improve the recovery of acute infectious diarrhea in 
adults (level of evidence 1b) however  more studies should be carried out since only very few strains of 
probiotics have been investigated.
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Efektivitas Probiotik pada Orang Dewasa dengan Diare: 
Sebuah Laporan Kasus Berbasis Bukti
Abstrak
Diare merupakan masalah kesehatan global dengan angka morbiditas dan mortalitas yang tinggi. Di 
negara berkembang, diare akut biasanya disebabkan oleh infeksi. Terlepas dari penyebabnya, tata laksana 
utama diare adalah terapi rehidrasi untuk mengurangi dehidrasi dan kematian walaupun hal tersebut tidak 
memengaruhi durasi diare. Probiotik dapat memperpendek durasi diare pada anak-anak, namun efektivitasnya 
pada orang dewasa masih belum jelas. Tujuan penelitian ini adalah untuk mengevaluasi efek probiotik dalam 
mengurangi durasi diare akut pada orang dewasa dibandingkan plasebo. Pencarian sistematik dilakukan 
pada empat database: PubMed, Scopus, ProQuest, dan Embase, tanpa membatasi tahun publikasi penelitian. 
Randomized clinical trial dipilih sebagai desain penelitian yang tepat untuk menjawab rumusan masalah 
dan dua penelitian dianggap relevan untuk ditelaah. Disimpulkan bahwa probiotik dapat mengurangi durasi 
diare akut akibat infeksi pada orang dewasa, namun perlu penelitian lebih lanjut karena hanya sedikit galur 
probiotik yang sudah diteliti.
Kata kunci: probiotik, efektivitas pengobatan, diare akut, dewasa
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Introduction
Diarrhea is defined by the WHO as three or 
more loose or watery stools in a 24-hour period 
and is termed acute diarrhea if it lasts less than 14 
days.1 As one of the most common gastrointestinal 
(GI) illnesses, diarrhea is a major health burden, 
causing approximately 1.78 million deaths (3.7% of 
total deaths) in low and middle-income countries in 
2001 and most of these deaths occurred in children 
under five years of age.2 In developing countries, 
acute diarrhea often occurs due to infection, where 
more than 20 viruses, bacteria, and parasites are 
associated with.3,4
Irrespective of the cause, diarrhea is mainly 
treated by fluid replacement therapy to decrease 
the risk of dehydration and death although it is 
ineffective in shortening the duration of diarrhea.5 
Diarrhea is usually self-limiting without the need 
for antibiotics and does not cause complications, 
however it may cause considerable discomfort 
that leads to loss of work and disturbance of social 
activities. As such, novel treatments that can reduce 
the duration of diarrhea are required.
WHO defined probiotics, as the live 
microorganisms that yield a health benefit on the 
host when given in adequate amounts. Probiotics 
have been shown effective in shortening the 
duration of diarrhea and in reducing stool frequency 
in children. 6,7 Whether similar benefits are present 
in adults, it is uncertain since few studies have been 
conducted in adults. Therefore, the aim of this study 
is to evaluate the efficacy of probiotic in adults with 
acute diarrhea through appraising existing medical 
evidences.
Case Illustration
 An eighty year-old male Indonesian came 
to a public hospital in Tangerang due to diarrhea 
since five days prior to admission. The patient 
approximately had five times of diarrhea per day, 
with liquid consistency, no blood, and not rice-
water-like appearance. There was no vomiting or 
abdominal pain, but the patient felt weak, nausea, 
and thirsty. Physical examination and routine blood 
tests were within normal limits and the patient was 
diagnosed with acute diarrhea with mild-moderate 
dehydration. After three days of inpatient care with 
supportive fluid therapy, the patient’s condition had 
improved favorably and thus was discharged.
Clinical Question
Is there any benefit of giving probiotic to adults 
with acute infectious diarrhea?
Methods
 A comprehensive computer-based literature 
search was performed using the electronic 
databases PubMed, Scopus, ProQuest, and 
Embase on February 2016. The search included 
Boolean combinations (AND, OR) of the 
following keywords: probiotic/ Bifidobacterium/
Enterococcus/Lactobacillus/Saccharomyces/
Streptococcus,treatment/ therapy efficacy/
effectiveness, acute diarrhea/gastroenteritis, adults. 
Limits of the search included ‘English’, ‘humans’, 
’full text available’, and ‘adult’. Year of publication 
was not limited. Multiple searches followed by 
manual screening of titles and abstracts were 
conducted to ensure that all the relevant studies 
were identified. Reference lists from the articles 
retrieved were manually assessed to identify 
additional relevant trials. The methodological 
quality and critical appraisal of the included studies 
were independently assessed using the Oxford 
model of evidence-based medicine.
Results
The literature search using the combinations 
of keywords and limits as mentioned above initially 
showed a total of 1.567 studies (Table 1), in which 
1.478 of them were considered irrelevant based on 
their title or abstract, thus were excluded (Figure 1). 
The remaining 89 studies were screened for double 
results, yielding 81 potentially relevant papers. 
Finally, 2 studies were included for critical appraisal 
following full text reading.
Efficacy of Probiotic in Adults 
59
Vol. 5, No. 1, April 2017
Table 1. Paper Search Terms and Results from Each Database
Databases Search terms Findings Used
PubMed
(probiotic OR Bifidobacterium OR Enterococcus OR 
Lactobacillus OR Saccharomyces OR Streptococcus) AND 
(treatment OR therapy) AND (efficacy OR effectiveness) AND 
(acute diarrhea OR gastroenteritis) 
104 1
Scopus
(probiotic OR Bifidobacterium OR Enterococcus OR 
Lactobacillus OR Saccharomyces OR Streptococcus) AND 
(treatment OR therapy) AND (efficacy OR effectiveness) AND 
(acute diarrhea OR gastroenteritis)
690 1
ProQuest
(probiotic OR Bifidobacterium OR Enterococcus OR 
Lactobacillus OR Saccharomyces OR Streptococcus) AND 
(treatment OR therapy) AND (efficacy OR effectiveness) AND 
(acute diarrhea OR gastroenteritis)
278 0
Embase
(probiotic OR Bifidobacterium OR Enterococcus OR 
Lactobacillus OR Saccharomyces OR Streptococcus) AND 
(treatment OR therapy) AND (efficacy OR effectiveness) AND 
(acute diarrhea OR gastroenteritis)
495 0
Total 1,567 2
Figure 1. Flowchart of the Searching Methods
Two relevant studies, Buydens et al8 and Wunderlich et al9 were critically appraised 
using oxford’s standardized validity, importance, and applicability assessments for therapy
studies (Table 2, Table 3, and Table 4). For the calculation of event rates in the 
assessment of importance (Table 3), an event is defined as diarrhea lasting ≥ 4 days,
whereas non-event is defined as diarrhea lasting <4 days. Description of each study is 
summarized in Table 5.
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Two relevant studies, Buydens et al8 and 
Wunderlich et al9 were critically appraised using 
oxford’s standardized validity, importance, and 
applicability assessments for therapy studies (Table 
2, Table 3, and Table 4). For the calculation of event 
rates in the assessment of importance (Table 3), 
an event is defined as diarrhea lasting ≥4 days, 
whereas non-event is defined as diarrhea lasting 
<4 days. Description of each study is summarized 
in Table 5.
Table 2. Assessment of Validity
Validity Buydens et al Wunderlich et al 
Was the assignment of patients to treatments  
randomized?
✓ ✓
Were the groups similar at the start of the trial? ✓ ✓
Aside from the allocated treatment,  were groups 
treated equally?
✓ ✓
Were all patients who entered the trial accounted for? 
– and were they analyzed in the groups to which they 
were randomized?
✓ ✓
Were measures objective or were the patients and 
clinicians kept “blind” to which treatment was being 
received?
✓ ✓
Table 3. Assessment of Importance
Importance Buydens et al Wunderlich et al
CER 0.15 0.41
EER 0 0.15
RR 0 0.37
ARR 0.15 0.26
RRR 1 0.63
NNT 6.67 3.85
CER: control event rate; EER: experimental event rate; RR: relative risk;
ARR: absolute risk reduction; RRR: relative risk reduction; NNT: number needed to treat
Table 4. Assessment of Applicability
Applicability Buydens et al Wunderlich et al
Is my patient so different to those in the study 
that the results cannot apply?
✓ ✓
Is the treatment feasible in my setting? ✓ ✓
Will the potential benefits of treatment outweigh 
the potential harms of treatment for my patient?
✓ ✓
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Table 5. Description of the Studies
Description Buydens et al Wunderlich et al
Methods Double-blind, randomized controlled trial in 
2 centers in Belgium.
Double-blind, randomized 
controlled trial in 10 centers in 
Switzerland and Lichtenstein.
Populations 185 participants; mean age 49 year-old.
Inclusion criteria: inpatients and 
outpatients; adults with acute diarrhea (≥3 
watery or loose stools in last 24 h).
Exclusion criteria: diarrhea <3 d; blood in 
feces; fecal leukocytes; temperature >39 
°C; friable and hemorrhagic mucosa in 
rectosigmoid; history of chronic diarrhea; 
polyps; colon cancer; Crohn’s disease; 
ulcerative colitis; malabsorption; use of 
antidiarrheals or antibiotics in past 7 d; 
severe diarrhea (dehydration with weight 
loss >10%); associated major diseases.
Number completing study: 93/105 (88.6%) 
in probiotic group and 92/106 (86.8%) in 
control group.
76 participants; mean age 33 
year-old.
Inclusion criteria: adults with 
acute diarrhea.
Exclusion criteria: not stated.
Number completing study: 40/47 
(85.1%) in probiotic group and 
38/46 (82.6%) in placebo group. 
Intervention Enterococcus strain SF68 (bioflorin; 75 x106 
CFU thrice daily for ≥5 d)
Live enterococcus strain SF 68 
(bioflorin; 75 x 106 CFU thrice 
daily for 7 d)
Comparison Placebo Placebo
Outcomes Number of participants with diarrhea by day 
of treatment.
Mean stool frequency by day of treatment.
No adverse effects due to probiotic.
Number of cases cured by day of 
treatment.
No adverse effects due to 
probiotic.
Notes Not stated: study duration, participants’ 
race, funding source.
Not stated: study duration; 
exclusion criteria; participants’ 
race; cause, characteristics, and 
duration of diarrhea; definition of 
cases cured; funding source.
Discussion
Normal gastrointestinal microbiota is known 
to play an important role in the protection of the 
host against gastrointestinal tract diseases and 
during acute diarrhea, it is shown to undergo 
major changes that promote the overgrowth of 
pathogenic microorganisms.10 Probiotics are 
potentially beneficial in an episode of infectious 
diarrhea by competing for available nutrients and 
binding sites with the enteric pathogens, acidifying 
the gut contents, generating a variety of protective 
chemicals, and stimulating specific and non-
specific immune responses.11
 Although there are some theoretical risks 
regarding the safety of probiotics, the use of 
probiotics is safe in healthy people, with rare cases 
of infections were found in those who had risk 
factors such as immune deficiency, short bowel, or 
using central venous catheters.12 
In contrast to the abundance of studies of 
probiotics efficacy in pediatric subjects with acute 
diarrhea, studies in adult subjects are very limited 
and thus only a couple of papers were appraised. 
Buydens et al8 conducted a randomized, double-
blind placebo-controlled clinical trial involving 211 
adults with acute diarrhea where the efficacy of 
enterococcus SF 68 strain, administered orally in 
a dose of 75xl06 colony-forming units (CFU) three 
times a day for 5 days, was compared with placebo. 
The probiotics-treated group had a significantly 
reduced mean duration of diarrhea (1.69 days) 
compared to control group (2.81 days) and after 
4 days of treatment, all of the subjects given 
probiotics no longer had diarrhea, whereas 15.22% 
of placebo-treated subjects still had diarrhea. No 
adverse effects were found in the treatment group.
Similarly, a randomized, double-blind placebo-
controlled clinical trial by Wunderlich et al9 assessing 
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123 patients with acute diarrhea demonstrated that 
enterococcus SF 68 given orally in a dose of 75xl06 
colony-forming units (CFU) thrice daily for 7 days 
significantly improved the recovery from diarrhea 
compared to placebo, i.e. 87.18% of those given 
probiotics were cured of diarrhea after 4 days of 
treatment, while only 59.46% of untreated subjects 
were cured. Adverse effects of probiotics were not 
assessed.
Interestingly, in contrast to the studies 
appraised in this paper, Mitra et al13 found that 
enterococcus SF 68 did not significantly reduce the 
stool output and mean duration of acute infectious 
diarrhea in adults compared to placebo, although 
they found that the probiotics were well-tolerated. It 
is speculated that this was due to the differences in 
study design, including the diarrhea was caused by 
the severe types of secretory diarrhea-producing 
Vibrio cholerae and enterotoxigenic Escherichia 
coli. The similar negativity of stool cultures between 
the two groups rendered the inability of the 
probiotics to inhibit the pathogens. This difference 
of result suggests that future studies should also 
include the etiology of the acute infectious diarrhea 
and the stool culture results.
The effects of probiotics are widely known to 
be strain-specific and thus results acquired from 
one probiotic cannot be extrapolated to other 
species, including closely related strains.14 As such, 
the efficacy of enterococcus SF 68 shown in this 
study cannot represent the efficacy of probiotics in 
general, although many studies involving various 
probiotics in various settings have mostly yielded 
positive outcomes, suggesting that most probiotics 
exert some common and effective mechanisms 
against a plethora of gastrointestinal pathogens.7 
Data regarding the treatment efficacy of 
various strain of probiotics in adults with acute 
diarrhea, is very limited. Margreiter et al15 
demonstrated that a combination of Lactobacillus 
gasseri and Bifidobacterium longum shortens the 
duration and decreases the severity of acute self-
limiting diarrhea in adults.16 The control group, was 
given Enterococcus feacium, not placebo. Sudha 
et al17 proposed that Bacillus clausii strain UBBC 
07 and Saccharomyces boulardii strain unique 28 
in patients suffering from acute diarrhea reduced 
the mean duration of diarrhea, the frequency of 
defecation, the severity of abdominal pain, and 
improved stool consistency compared to placebo, 
with no significant adverse effect. Both studies, 
however, were still preliminary as no control group 
was present. More studies with various strain is 
necessary to investigate the efficacy of probiotics 
in adults with acute infectious diarrhea.
The existing clinical trials also had a substantial 
limitation where the definition of diarrheal episodes 
varies and this may lead to misclassification and 
difficulty in comparing the outcomes.18 Future research 
should standardize the definitions of acute diarrhea, 
treatment regimens, inclusion criteria, and outcome 
measures to allow good comparison of results across 
studies. Indeed, host and environmental factors, 
including age, diet and eating practices, level of 
sanitation, and exposure to antibiotics, may determine 
the commensal gut flora, and thus may alter probiotic 
efficacy.19,20 Age, for instance, matters since there 
are differences in the diversity and maturation of 
microbiota composition in adults compared to children 
as found in the fecal samples and thus study results 
in children may not be applied to adults. 21 Since most 
cases of acute diarrhea are uncomplicated, self-limiting 
and need no specific treatment, cost-effectiveness 
analyses might be necessary, particularly for the 
patients in the developing countries.7 Addressing all 
these issues would build a good foundation to create 
comprehensive evidence-based treatment guidelines.
Conclusion 
Probiotics, specifically enterococcus SF 
68, could improve the recovery and shorten the 
course of acute infectious diarrhea in adults, with 
no reported adverse effect (level of evidence 1b). 
Recommending the utilization of probiotics in adults 
with acute infectious diarrhea, however, should be 
proceeded with caution due to the limited availability 
and marked clinical variability of existing studies.
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